Alamar Biosciences (ALMR) Registration filing summary

Company overview and business model

• Commercial-stage proteomics company offering ultra-sensitive, multiplexed protein detection and analysis for research and future diagnostics.

• Proprietary NULISA technology enables detection of low-abundance biomarkers in biofluids with high sensitivity, specificity, and automation.

• Business model centers on sales of ARGO HT instruments, consumables, and analytical software, with a razor/razor blade approach.

• Customers include top research institutions, biopharma, CROs, and service labs across 25 countries.

• Platform currently for research use only, with plans to expand into clinical diagnostics.

Financial performance and metrics

• 2025 revenue: $74.2M, up 195% from $25.1M in 2024.

• Gross margin improved from 34% (2024) to 56% (2025).

• Net losses: $47.1M (2024), $29.8M (2025); accumulated deficit of $168.8M as of Dec 31, 2025.

• Instrument installed base grew from 36 (2024) to 102 (2025); >$400K average annual consumable pull-through per instrument in 2025.

• Q1 2026 estimated revenue: $25.2M–$26.2M, up from $13.1M in Q1 2025.

Use of proceeds and capital allocation

• Net proceeds of ~$133.2M (or ~$154.1M if underwriters' option exercised) expected, based on $16.00/share IPO price.

• Proceeds to be used for working capital, operating expenses, capital expenditures, and general corporate purposes.

• Potential for strategic investments in complementary businesses, products, or technologies.